PMV Pharmaceuticals Announces Updated Rezatapopt Ovarian Cancer Data

What Happened

• On August 31, 2026, PMV Pharmaceuticals, Inc. (PMVP) filed an 8-K under Item 8.01 to report updated interim ovarian cancer data for rezatapopt given as monotherapy from the pivotal Phase 2 portion of the PYNNACLE clinical trial. The company issued a press release describing the data; that release is attached as Exhibit 99.1 and is incorporated by reference.

Key Details

• Date filed: August 31, 2026 (8-K reporting the press release).
• Drug: rezatapopt (monotherapy).
• Study: Updated interim data from the Phase 2 pivotal portion of the PYNNACLE trial (ovarian cancer).
• Exhibit: Press release dated August 31, 2026 filed as Exhibit 99.1.

Why It Matters

• Clinical data updates are key development milestones for biotech investors because they can affect the program’s regulatory path, partner interest, and investor sentiment. This 8-K signals PMV is advancing rezatapopt’s pivotal Phase 2 program and is publicly disclosing interim results.
• The filing does not include financial results or management changes; investors should review the attached press release for the specific data points and watch for future regulatory filings or company updates that provide additional details.